HepQuant
Business Services · Colorado, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
8110 E Union Ave Ste 750, Denver, Colora...Phone Number
(303) 923-2242Website
www.hepquant.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About HepQuant
HepQuant specializes in non-invasive, blood-based quantitative tests that assess liver health, specifically aimed at managing patients with liver diseases. Their primary product, HepQuant DuO, delivers a Disease Severity Index (DSI) to support healthcare providers in making informed clinical decisions. The company caters to healthcare providers, including clinicians and drug developers, by enabling effective management and risk stratification of patients with liver conditions. HepQuant also emphasizes their commitment to innovating liver disease management through continuous advancements in their testing solutions.Explore more
HepQuant Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is HepQuant your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
HepQuant, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once HepQuant has new funding data
Product Launch: Get notified when HepQuant launches new products
Click to see if HepQuant had a recent Job posting/layoffs
Check if HepQuant has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at HepQuant
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on HepQuant recently announced quarterly report
Check out if HepQuant is spiking on competitors!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to HepQuant
Compare insights from companies similar to HepQuant, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
HepQuant is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
HepQuant is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about HepQuant.
HepQuant financials insights
Gather financial insights about HepQuant, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Debt
$150K
2021
Debt
$191K
HepQuant Tech Stack
A closer look at the technologies used by HepQuant
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Person-Based
Person-Based
Project
Research & Development, Medical Research, Healthcare Technology
Person-Based
HepQuant News & Media
Three Presentations at EASL 2026 Highlight the Clinical and Drug Development Value of HepQuant DuO®
HepQuant, LLC announced the presentation of three studies at the 2026 Congress of the European Association for the Study of the Liver (EASL), showcasing the clinical and research value of the HepQuant DuO® test and its Disease Severity Index (DSI). Data presented in three abstracts as...2026 DDW Oral Presentation: HepQuant DuO® Disease Severity Index (DSI) Outperforms Child-Pugh and MELD Scores in Predicting Risk of Esophageal Varices
HepQuant, a leader in developing noninvasive, blood-based, quantitative testing to assess liver health, is excited to announce an oral presentation at Digestive Disease Week (DDW) 2026. Presented data findings highlight that the HepQuant DuO Disease Severity Index (DSI) Outperforms...2026 MASH-TAG Oral Presentation: HepQuant DuO® Reveals Functional and Physiological Heterogeneity to Support Enhanced Clinical Trial Design
HepQuant, a leader in developing noninvasive, blood-based, quantitative testing to assess liver health, presented oral and poster data findings at the 2026-MASH-TAG conference January 8-10, 2026, Park City, UT. The presentation by Dr. Gregory T. Everson titled "Understanding the...HepQuant Presents Exciting Abstracts at The Liver Meeting 2025 Demonstrating HepQuant DuO® Utility to Uncover Functional and Physiological Heterogeneity
HepQuant, a leader in developing noninvasive, blood-based, quantitative testing to assess liver health, will present three exciting abstracts demonstrating HepQuant DuO utility at The Liver Meeting 2025® conference this week. Each demonstrates how HepQuant DuO test results uncover...
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding HepQuant
Sign Up For FreeTo access detailed company insights
HepQuant specializes in non-invasive, blood-based quantitative tests that assess liver health, specifically aimed at managing patients with liver diseases. Their primary product, HepQuant DuO, delivers a Disease Severity Index (DSI) to support healthcare providers in making informed clinical decisions. The company caters to healthcare providers, in... Read More
